Indaptus Therapeutics (NASDAQ:INDP) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(1.57) by 98.73 percent. This is a 99.78 percent increase over losses of $(9.09) per share from the same period last year.